Prenylated flavonoid morusin protects against TNBS-induced colitis in rats.
PLoS One
; 12(8): e0182464, 2017.
Article
em En
| MEDLINE
| ID: mdl-28797051
ABSTRACT
Morusin is a prenylated flavonoid isolated from the root bark of Morus alba. Many studies have shown the ability of flavonoids to act as anti-inflammatory agents. The aim of this study was to evaluate the effect of morusin on experimentally colitis induced by 2,4,6-trinitrobenzensulfonic acid in Wistar rats and to compare it with sulfasalazine, a drug conventionally used in the treatment of inflammatory bowel disease. Morusin was administered by gavage at doses of 12.5, 25, or 50 mg/kg/day for five days. The colonic tissue was evaluated macroscopically, histologically, and by performing immunodetection and zymographic analysis to determine the levels of antioxidant enzymes [superoxide dismutase (SOD) and catalase (CAT)], interleukin (IL)-1ß, and transforming growth factor (TGF)-ß1 and the activities of matrix metalloproteinases (MMP) 2 and 9. The tissue damage scores were significantly reduced with increasing dose of morusin, however efficacy was not demonstrated at the highest dose. At the dose of 12.5 mg/kg, morusin exerted therapeutic effectivity similar to that of sulfasalazine (50 mg/kg). This was associated with significant reduction of TGF-ß1 levels and MMP2 and MMP9 activities, and slight reduction of IL-1ß. Our results suggest that morusin possesses therapeutic potential for the treatment of chronic inflammatory diseases.
Texto completo:
1
Base de dados:
MEDLINE
Assunto principal:
Flavonoides
/
Colite
Limite:
Animals
Idioma:
En
Ano de publicação:
2017
Tipo de documento:
Article